Entos is now Iambic Therapeutics
Read more
Platform
Pipeline
Partnerships
News & Media
About
Careers
Contact
Contact
Publications
back to blog
A potent and highly selective irreversible HER2 inhibitor for treating HER2-driven cancers
Publications
This is some text inside of a div block.
April 18, 2023
Media Contacts
Related announcements
View All
View All
September 5, 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Read more
September 5, 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Read more
June 18, 2024
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
Read more
June 18, 2024
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
Read more
June 18, 2024
How two academic chemists turned San Diego startup Iambic into an AI force
Read more
June 18, 2024
How two academic chemists turned San Diego startup Iambic into an AI force
Read more